Market Research Logo

Global Non-alcoholic Steatohepatitis Market 2016-2020

About Non-Alcoholic Steatohepatitis (NASH)

NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH.

Technavio’s analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global NASH Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Arena Pharmaceuticals
  • AstraZeneca
  • F Hoffmann-La Roche
  • GSK
  • Novo Nordisk
  • Vivus
Other prominent vendors
  • Arisaph Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead
  • Immuron
  • Interceptpharma
  • Raptor Pharmaceutical
  • Shire
  • Tobira Therapeutics
  • Verva
  • Viking Therapeutics
Market driver
  • Increase in sedentary lifestyle
  • For a full, detailed list, view our report
Market challenge
  • Limited understanding of disease pathophysiology
  • For a full, detailed list, view our report
Market trend
  • Patient assistance programs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Non-Alcoholic Steatohepatitis (NASH) Market 2016-2020

Technavio recognizes the following companies as the key players in the global non-alcoholic steatohepatitis (NASH) market: Arena Pharmaceuticals, AstraZeneca, F Hoffmann-La Roche, GSK, Novo Nordisk, and Vivus.

Other Prominent Vendors in the market are: Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, and Viking Therapeutics.

Commenting on the report, an analyst from Technavio’s team said: “One noteworthy trend in the market is the availability of patient assistance programs. Patient assistance programs offered by vendors, designed to fit individual needs regarding liver diseases, help them attain access to medications. AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Novo Nordisk are among the companies that offer patient assistance programs, offering solutions such as co-pay assistance and coupons.”

According to the report, a key driver of market growth is an increasingly sedentary lifestyle. An unhealthy or sedentary lifestyle and the intake of high calorie food results in the accumulation of excess body fat, causing problems such as obesity, diabetes, cardiovascular problems, and liver disease, which are the associated conditions for NASH. This provides drug manufacturers with opportunities to manufacture new and effective drugs, thereby boosting the growth of the global NASH drugs market.

Further, the report states that one challenge that could severely impact market growth is the limited understanding of the disease’s pathophysiology.

Companies Mentioned

Arena Pharmaceuticals, AstraZeneca, F Hoffmann-La Roche, GSK, Novo Nordisk, Vivus, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Immuron, Interceptpharma, Raptor Pharmaceutical, Shire, Tobira Therapeutics, Verva, Viking Therapeutics.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Disease overview
    • Understanding the disease
    • Symptoms and signs
    • Pathophysiology
    • Risk factors
      • Table Conditions associated with NASH
    • Diagnosis
      • Table Diagnosis of NASH
    • Treatment
    • Epidemiology
    • Economic burden
  • Pipeline analysis
    • Table Global NASH drugs market: Pipeline portfolio
    • Pipeline information of NASH
    • Clinical trials for NASH
      • Table Clinical trials for NASH by development phase
      • Table Clinical trials for NASH by trial status
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global NASH drugs market 2015-2020 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by dosage form
    • Table Segmentation of global NASH drugs market by dosage form
    • Solid
    • Liquid
  • Market segmentation by route of administration
    • Table Segmentation of global NASH drugs market by route of administration
    • Oral
    • Parenteral
  • Geographical segmentation
    • Global NASH drugs market by geographical segmentation 2015-2020
      • Table Global NASH drugs market by geographical segmentation 2015
      • Table Global NASH drugs market revenue by geography 2015-2020 ($ millions)
    • NASH drugs market in Americas
      • Table NASH drugs market in Americas 2015-2020 ($ millions)
    • NASH drugs market in US
      • Table NASH market in US 2015-2020 ($ millions)
    • NASH drugs market in EMEA
      • Table NASH drugs market in EMEA 2015-2020 ($ millions)
    • NASH drugs market in APAC
      • Table NASH drugs market in APAC 2015-2020 ($ millions)
  • Market drivers
    • Increase in sedentary lifestyle
    • Prevalence of associated health conditions
    • Promising pipeline
    • Significant unmet medical needs
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Limited understanding of disease pathophysiology
    • Insufficient diagnostic technology for NASH
    • Stringent regulatory procedure
    • Adverse effects of drugs
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Rise in public awareness
    • Increase in strategic alliances
    • Patient assistance programs
    • Usage of off-label drugs
  • Vendor landscape
    • Competitive scenario
    • Arena Pharmaceuticals
      • Table Arena Pharmaceuticals: YoY revenue of Belviq 2013-2014 ($ millions)
      • Table Arena Pharmaceuticals: Key takeaways
    • AstraZeneca
      • Table AstraZeneca: Cardiovascular and metabolic diseases segmentation by revenue 2013 and 2014 ($ billions)
      • Table Top selling products in 2014 ($ millions)
      • Table AstraZeneca: YoY growth and revenue of Bydureon 2012-2014 ($ millions)
      • Table AstraZeneca: YoY growth and revenue of Byetta 2012-2014 ($ millions)
      • Table AstraZeneca: YoY growth and revenue of Onglyza/ Komboglyze/ Komboglyze XR 2012-2014 ($ millions)
      • Table AstraZeneca: Key takeaways
    • F Hoffmann-La Roche
      • Table Roche: Key takeaways
    • GSK
      • Table GSK: Key takeaways
    • Novo Nordisk
      • Table Novo Nordisk: Business segmentation by revenue 2014
      • Table Novo Nordisk: R&D expenditure 2014
      • Table Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2012-2014 ($millions)
      • Table Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2012-2014 ($millions)
      • Table Novo Nordisk: YoY growth and revenue of Prandin 2012-2014 ($ millions)
      • Table Novo Nordisk: Key takeaways
    • Vivus
      • Table Vivus: YoY growth and revenue of Qsymia 2012-2014 ($ millions)
      • Table Vivus: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report